Literature DB >> 9213079

A naturalistic study of paroxetine in premenstrual syndrome: efficacy and side-effects during ten cycles of treatment.

C Sundblad1, I Wikander, B Andersch, E Eriksson.   

Abstract

Eighteen women with severe premenstrual syndrome (PMS) (premenstrual dysphoric disorder, PMDD) were treated openly with paroxetine for 10 consecutive menstrual cycles. Dosage was flexible (5-30 mg/day); also, the patients were free to chose between continuous medication and medication in the luteal phase only. The rating of premenstrual irritability, depressed mood, increase in appetite, and anxiety/tension was markedly lower during treatment with paroxetine than before, and this reduction in symptomatology appeared unabated for the entire treatment period. Sedation, dry mouth, and nausea were common side-effects but declined during the course of the trial; in contrast, reduced libido and anorgasmia, which were reported by almost 50% of the participants, were not improved with time. The results indicate that the beneficial effects as well as the sexual side-effects of serotonin reuptake inhibitors persist unchanged for at least 10 consecutive cycles of treatment.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9213079     DOI: 10.1016/s0924-977x(97)00404-5

Source DB:  PubMed          Journal:  Eur Neuropsychopharmacol        ISSN: 0924-977X            Impact factor:   4.600


  10 in total

Review 1.  The role of central serotonergic dysfunction in the aetiology of premenstrual dysphoric disorder: therapeutic implications.

Authors:  B L Parry
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

2.  Paroxetine Controlled Release for Premenstrual Dysphoric Disorder: Remission Analysis Following a Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Teri B Pearlstein; Kevin M Bellew; Jean Endicott; Meir Steiner
Journal:  Prim Care Companion J Clin Psychiatry       Date:  2005

Review 3.  Selective serotonin reuptake inhibitors for premenstrual syndrome.

Authors:  Jane Marjoribanks; Julie Brown; Patrick Michael Shaughn O'Brien; Katrina Wyatt
Journal:  Cochrane Database Syst Rev       Date:  2013-06-07

4.  Premenstrual dysphoric disorder: evidence for a new category for DSM-5.

Authors:  C Neill Epperson; Meir Steiner; S Ann Hartlage; Elias Eriksson; Peter J Schmidt; Ian Jones; Kimberly A Yonkers
Journal:  Am J Psychiatry       Date:  2012-05       Impact factor: 18.112

Review 5.  Luteal phase administration of agents for the treatment of premenstrual dysphoric disorder.

Authors:  Ellen W Freeman
Journal:  CNS Drugs       Date:  2004       Impact factor: 5.749

Review 6.  Update on research and treatment of premenstrual dysphoric disorder.

Authors:  Joanne Cunningham; Kimberly Ann Yonkers; Shaughn O'Brien; Elias Eriksson
Journal:  Harv Rev Psychiatry       Date:  2009       Impact factor: 3.732

Review 7.  Selective serotonin reuptake inhibitors for premenstrual dysphoric disorder: the emerging gold standard?

Authors:  Teri Pearlstein
Journal:  Drugs       Date:  2002       Impact factor: 9.546

8.  Premenstrual syndrome.

Authors:  Kimberly Ann Yonkers; P M Shaughn O'Brien; Elias Eriksson
Journal:  Lancet       Date:  2008-04-05       Impact factor: 79.321

Review 9.  Current management of premenstrual syndrome and premenstrual dysphoric disorder.

Authors:  L Born; M Steiner
Journal:  Curr Psychiatry Rep       Date:  2001-12       Impact factor: 8.081

10.  Effect of Garlic (Allium sativum) Supplementation on Premenstrual Disorders: A Randomized, Double-Blind, Placebo-Controlled Trial.

Authors:  Fatemeh Jafari; Malihe Tabarrai; Alireza Abbassian; Farhad Jafari; Mohammad Hossein Ayati
Journal:  Evid Based Complement Alternat Med       Date:  2021-11-01       Impact factor: 2.629

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.